{"id":"cyt003-qbg10","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by inducing regulatory T cells to suppress the activity of autoreactive T cells, thereby reducing inflammation and tissue damage. This mechanism is thought to be beneficial in treating conditions such as multiple sclerosis and rheumatoid arthritis.","oneSentence":"CYT003-QbG10 is a therapeutic vaccine designed to treat autoimmune diseases by modulating the immune response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:30:24.640Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis"},{"name":"Rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT04387071","phase":"PHASE1, PHASE2","title":"CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2021-04-29","conditions":"Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":2},{"nctId":"NCT05445609","phase":"PHASE2","title":"Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer","status":"SUSPENDED","sponsor":"Emory University","startDate":"2023-06-07","conditions":"Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":10},{"nctId":"NCT03983668","phase":"PHASE1, PHASE2","title":"CMP-001 for Relapsed and Refractory Lymphoma","status":"COMPLETED","sponsor":"Umar Farooq","startDate":"2020-01-31","conditions":"Lymphoma","enrollment":14},{"nctId":"NCT01673672","phase":"PHASE2","title":"CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma","status":"TERMINATED","sponsor":"Cytos Biotechnology AG","startDate":"2012-11","conditions":"Moderate to Severe Allergic Asthma","enrollment":365},{"nctId":"NCT02087644","phase":"PHASE2","title":"CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids","status":"WITHDRAWN","sponsor":"Cytos Biotechnology AG","startDate":"2014-05","conditions":"Asthma","enrollment":""},{"nctId":"NCT00574704","phase":"PHASE2","title":"A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis","status":"COMPLETED","sponsor":"Cytos Biotechnology AG","startDate":"2006-09","conditions":"Perennial Allergic Rhinoconjunctivitis, House Dust Mite Allergy","enrollment":40},{"nctId":"NCT00890734","phase":"PHASE2","title":"CYT003-QbG10 for Treatment of Allergic Asthma Bronchial","status":"COMPLETED","sponsor":"Cytos Biotechnology AG","startDate":"2009-04","conditions":"Allergic Bronchial Asthma","enrollment":63},{"nctId":"NCT00800332","phase":"PHASE2","title":"Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy","status":"COMPLETED","sponsor":"Cytos Biotechnology AG","startDate":"2008-11","conditions":"Rhinoconjunctivitis, Allergies","enrollment":300},{"nctId":"NCT00575003","phase":"PHASE2","title":"Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis","status":"COMPLETED","sponsor":"Cytos Biotechnology AG","startDate":"2007-12","conditions":"Perennial Allergy to House Dust Mite and/or Cat","enrollment":64},{"nctId":"NCT00574223","phase":"PHASE2","title":"A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis","status":"COMPLETED","sponsor":"Cytos Biotechnology AG","startDate":"2007-11","conditions":"Perennial Allergic Rhinoconjunctivitis, House Dust Mite Allergy","enrollment":100},{"nctId":"NCT00652223","phase":"PHASE1, PHASE2","title":"Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy","status":"COMPLETED","sponsor":"Cytos Biotechnology AG","startDate":"2005-03","conditions":"Perennial Allergic Rhinoconjunctivitis, Allergic Asthma","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CYT003-QbG10","genericName":"CYT003-QbG10","companyName":"Cytos Biotechnology AG","companyId":"cytos-biotechnology-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CYT003-QbG10 is a therapeutic vaccine designed to treat autoimmune diseases by modulating the immune response. Used for Relapsing-remitting multiple sclerosis, Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}